Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate ...

CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate ...

Median progression-free survival (PFS) increased from 7.4 months with stereotactic body radiotherapy (SBRT) to 17.6 months with the addition of 177 lutetium (Lu) PNT2002 targeting prostate-specific ...

A total of 295 eligible patients were enrolled with a median follow-up of 5.0 years. The arms were well balanced, with a median age of 65 years (IQR 59-71), 50% with positive surgical margins, 51% ...

The 2025 ASTRO annual meeting featured a prostate cancer session and a presentation by Dr. Angela Jia discussing the clinical ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived ...

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that the PAM50 ...

Use of PSMA PET/CT imaging before salvage radiotherapy was linked to improved survival for patients with BCR prostate cancer ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data for a molecular signature to predict hormone therapy benefit in men ...